Reading Time: 3 minutesGuest researcher blog post written by Lucy Musson. My name is Lucy Musson and I am a Research Assistant working at the Sheffield Institute for
Category: Treatments
Reading Time: 2 minutesThis week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Reading Time: 3 minutesA recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug
Reading Time: 5 minutesLast Thursday marked an exciting milestone in the search for effective therapies for MND as full results from the early-phase 1/2 trial of Biogen’s tofersen
Reading Time: 4 minutesAlthough ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in
Reading Time: 5 minutesThis blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 4 minutesThis blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 3 minutesTUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure
Reading Time: 5 minutesThere are literally thousands of websites on the internet that make claims about amazing alternative or off-label treatments (AOTs) and even cures for MND but
Reading Time: 2 minutesThis article was written by Dr Keith Mayl and Dr Ahmad Al Khleifat of King’s College London. Researchers at King’s College Hospital, led by Professor